We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.28 | 0.64% | 43.98 | 648 | 09:48:11 |
From May 2019 to May 2024
By Colin Kellaher
Bristol Myers Squibb Co. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Onureg as a maintenance therapy in certain patients with acute myeloid leukemia.
The New York biopharmaceutical company said the recommendation covers adults who achieved complete remission or complete remission with incomplete blood count recovery following induction therapy with or without consolidation treatment and who aren't candidates for hematopoietic stem-cell transplantation.
Bristol Myers said Onureg, if approved, would be the first and only once-daily oral frontline maintenance therapy in Europe to show significant overall survival in patients with a broad range of acute myeloid leukemia subtypes in first remission.
The European Commission, which generally follows CHMP's advice, will review the recommendation and is expected to make a final decision within 67 days of receipt, the company said.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 23, 2021 07:33 ET (11:33 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
